Back to discover
Disease

Whooping Cough

Late-stage therapeutic developmentEmerging research
MeSHWhooping Cough
2
Publications
12
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunizations: We must do better…now.

Research2024-07-02International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

Research2018-04-01The Journal of infectious diseases

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones4View
Results posted 1
Results expected 2
Recently completed 1
Activity timeline4

Clinical trials

9 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
12
All trials
4
Active
4
Late-stage
6
Completed
Late-stage studies

Phase III Clinical Trials to Evaluate the Immunogenicity and Safety of Adsorption-free Diphtheria and Tetanus (Three-component) Combined Vaccine in 2-month-old Infants and Young Children

Phase 3 · Recruiting · Changchun BCHT Biotechnology Co.

A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 Months

Phase 3 · Active, not recruiting · China National Biotec Group Company Limited

A Phase II/III Randomized, Observer-blind, Active-controlled Study to Compare Non-inferior Immunogenicity of a DTaPgen Vaccine to a Licensed DTaP-IPV, When Administered to Healthy Toddlers Aged of 15-36 Months Old.

Phase 2/3 · Completed · BioNet-Asia Co., Ltd.

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Phase 4 · Completed · Sanofi Pasteur, a Sanofi Company
Recently completed

Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)

Phase 2 · Completed · ILiAD Biotechnologies

A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis

Phase 2 · Completed · ILiAD Biotechnologies

A Phase II/III Randomized, Observer-blind, Active-controlled Study to Compare Non-inferior Immunogenicity of a DTaPgen Vaccine to a Licensed DTaP-IPV, When Administered to Healthy Toddlers Aged of 15-36 Months Old.

Phase 2/3 · Completed · BioNet-Asia Co., Ltd.

A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults

Phase 1 · Completed · DBV Technologies

A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine; A Randomized Placebo-controlled Dose-escalating Study of Single-use GamLPV Safety and Tolerability in Healthy Human Volunteers

Phase 1 · Completed · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Phase 4 · Completed · Sanofi Pasteur, a Sanofi Company

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182024
Most influential

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunizations: We must do better…now.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024 · 35 cites

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

The Journal of infectious diseases · 2018 · 35 cites
Recent publications

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunizations: We must do better…now.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024 · 35 cites

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.

The Journal of infectious diseases · 2018 · 35 cites
Major themes4
  • Bordetella pertussis1
  • COVID-191
  • Pertussis Vaccine1
  • Whooping Cough1
Leading journals2
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases1
  • The Journal of infectious diseases1
Leading researchers8
  • Amirthalingam G1
  • Beran J1
  • Campbell H1
  • Chu L1
  • David MP1
  • Dieussaert I1
  • Domachowske JB1
  • Fissette LA1
Affiliations (unnormalised)6
  • Clinical Research and Development1
  • Johnson County Clinic Trials1
  • Karolinska Institute1
  • St George's Hospital1
  • SUNY Upstate Medical Center1
  • UK; Paediatric Infectious Diseases Research Group and Vaccine Institute1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.

Identifiers
MeSHWhooping Cough
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.